Literature DB >> 33333046

Involvement of the NLRC4 inflammasome in promoting retinal ganglion cell death in an acute glaucoma mouse model.

Ke Yao1, Yin Zhao1, Peiming Jin1, Xiaotong Lou1, Zhaoxia Luo1, Hong Zhang1, Fei Li2.   

Abstract

PURPOSE: To explore the role of nucleotide-binding oligomerization domain-like receptors (NLRs) family caspase-activation and the recruitment domain containing 4 (NLRC4) inflammasome in retinal ganglion cell (RGC) injury induced by an acute glaucoma mouse model.
METHOD: A mouse model of acute ocular hypertension, which can lead to retinal ischemia-reperfusion (I/R) injury, was established. The expression level of NLRC4 was detected by polymerase chain reaction and western blotting. Localized expression of NLRC4 was detected by examining immunofluorescence in eyeball sections. Intravitreal adeno-associated virus 2(AAV2) administration was used to knockdown retinal Nlrc4. Fluoro-Gold labeled RGCs and TdT-mediated dUTP nick end labeling were used to evaluate the survival and apoptosis of RGCs. Tlr4-/- mice were utilized to explore whether NLRC4 inflammasome is influenced by Toll-like receptor4 (TLR4).
RESULTS: NLRC4, expressed in RGCs and microglial cells, was actively involved in mouse retinal I/R injury. Knockdown of Nlrc4 using an AAV2 vector caused an obvious reduction in the generation of IL-1β led by the rapidly elevated intraocular pressure, and thereby improved the RGC survival. In addition, activation of the NLRC4 inflammasome could influence the phosphorylation of p38 and Jun N-terminal kinase, which was largely dependent on TLR4 signaling.
CONCLUSION: Our study demonstrated the role of NLRC4 inflammasome in promoting RGC damage in mouse retinal I/R injury. Inhibition of NLRC4 might be leveraged as a potential therapeutic target in glaucomatous retinopathy.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Acute glaucoma; Adeno-associated virus 2; NLRC4 inflammasome; Retinal ischemia-reperfusion

Mesh:

Substances:

Year:  2020        PMID: 33333046     DOI: 10.1016/j.exer.2020.108388

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  4 in total

Review 1.  Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases.

Authors:  Meini Chen; Rong Rong; Xiaobo Xia
Journal:  J Neuroinflammation       Date:  2022-07-14       Impact factor: 9.587

Review 2.  Pyroptosis: A New Insight Into Eye Disease Therapy.

Authors:  Yun Zhang; Yan Jiao; Xun Li; Sheng Gao; Nenghua Zhou; Jianan Duan; Meixia Zhang
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

3.  Covalent Organic Framework (COF): A Drug and Carrier to Attenuate Retinal Ganglion Cells Death in an Acute Glaucoma Mouse Model.

Authors:  Ke Yao; Xin Liang; Guiyang Zhang; Yan Rong; Qiuxiang Zhang; Qiaobo Liao; Hong Zhang; Kai Xi; Junming Wang
Journal:  Polymers (Basel)       Date:  2022-08-10       Impact factor: 4.967

4.  Olaparib, a PARP-1 inhibitor, protects retinal cells from ocular hypertension-associated oxidative damage.

Authors:  Yuting Yang; Jihong Wu; Wei Lu; Yiqin Dai; Youjia Zhang; Xinghuai Sun
Journal:  Front Cell Dev Biol       Date:  2022-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.